Antiretroviral therapy and dyslipidaemia: Unlocking the code

PLoS Medicine

Volumn 3, Issue 3, 2006, Pages 291-293

  Mallon, Patrick W G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN C3; INSULIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN C;

ALLELE; DISEASE SEVERITY; DOWN REGULATION; DYSLIPIDEMIA; ENZYME REGULATION; ETHNIC DIFFERENCE; GENE SEQUENCE; HAPLOTYPE; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; METABOLIC SYNDROME X; PREVALENCE; PROTEIN EXPRESSION; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; CHEMICALLY INDUCED DISORDER; ETHNIC GROUP; GENETIC POLYMORPHISM; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHYSIOLOGY; RACE; REVIEW;

ANTI-RETROVIRAL AGENTS; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; CONTINENTAL POPULATION GROUPS; DYSLIPIDEMIAS; ETHNIC GROUPS; HIV INFECTIONS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TRIGLYCERIDES;

EID: 33645348526     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030085     Document Type: Short Survey

References (30)

1. Grinspoon S, Carr A (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352: 48-62.
2. Carr A, Samaras K, Burton S, Law M, Freund J, et al. (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58.
3. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, et al. (2000) Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14: 51-57.
4. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349: 1993-2003.
5. Mallon PW, Unemori P, Sedwell R, Morey A, Rafferty M, et al. (2005) In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 191: 1686-1696.
6. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, et al. (2001) The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50: 1378-1388.
7. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, et al. (2001) HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 7: 1327-1331.
8. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, et al. (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409: 928-933.
9. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 286: 2270-2279.
10. Lai CQ, Parnell LD, Ordovas JM (2005) The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol 16: 153-166.
11. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, et al. (2000) VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102: 1886-1892.
12. Rimland D, Guest JL, Hernandez I, Del Rio C, Le NA, et al. (2005) Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins. HIV Med 6: 326-333.
13. Bonnet E, Ruidavets JB, Tuech J, Ferrieres J, Collet X, et al. (2001) Apoprotein c-III and Econtaining lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: Association with the development of lipodystrophy. J Clin Endocrinol Metab 86: 296-302.
14. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, et al. (1995) Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 96: 2601-2605.
15. Fauvel J, Bonnet E, Ruidavets JB, Ferrieres J, Toffoletti A, et al. (2001) An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 15: 2397-2406.
16. Tarr PE, Taffe P, Bleiber G, Furrer H, Rotger M, et al. (2005) Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 191: 1419-1426.
17. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL (1993) An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci U S A 90: 4562-4566.
18. Joint United Nations Programme on HIV/ AIDS, NetLibrary, World Health Organization (2005) AIDS epidemic update December 2005. Geneva: Joint United Nations Programme on HIV/AIDS. 98 p.
19. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 287: 356-359.
20. Foulkes AS, Wohl DA, Frank I, Puleo E, Restine S, et al. (2006) Associations among race/ethnicity, apoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med 3: e52. DOI: 10.1371/journal.pmed.0030052
21. Haas DW, Wilkinson GR, Kuritzkes DR, Richman DD, Nicotera J, et al. (2003) A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials 4: 287-300.
22. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, et al. (2004) Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 18: 2391-2400.
23. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, et al. (2002) Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 359: 30-36.
24. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, et al. (2005) Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 15: 1-5.
25. Mallal S, Nolan D, Witt C, Masel G, Martin AM, et al. (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359: 727-732.
26. Miserez AR, Muller PY, Barella L, Schwietert M, Erb P, et al. (2001) A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS 15: 2045-2049.
27. Yang A, King MS, Han L, Isaacson JD, Mueller T, et al. (2003) Lack of correlation between SREBF1 genotype and hyperlipidemia in individuals treated with highly active antiretroviral therapy. AIDS 17: 2142-2143.
28. Nolan D, Moore C, Castley A, Sayer D, Mamotte C, et al. (2003) Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 17: 121-123.
29. Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, et al. (2002) TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 16: 2013-2018.
30. de Montgolfier S, Moutel G, Duchange N, Theodorou I, Herve C, et al. (2002) Ethical re. ections on pharmacogenetics and DNA banking in a cohort of HIV-infected patients. Pharmacogenetics 12: 667-675.